Bio Impact Capital LLC Avadel Pharmaceuticals PLC Call Options Transaction History
Bio Impact Capital LLC
- $611 Million
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AVDL
# of Institutions
132Shares Held
68.4MCall Options Held
1.01MPut Options Held
2.03M-
Janus Henderson Group PLC London, X012.9MShares$197 Million0.12% of portfolio
-
Rtw Investments, LP New York, NY8.8MShares$134 Million2.38% of portfolio
-
Polar Capital Holdings PLC London, X06.75MShares$103 Million0.71% of portfolio
-
Gendell Jeffrey L Greenwich, CT5.71MShares$87 Million3.76% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.97MShares$60.6 Million8.97% of portfolio
About AVADEL PHARMACEUTICALS PLC
- Ticker AVDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 60,581,300
- Market Cap $924M
- Description
- Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...